Evidence-based review of statin use in patients with HIV on antiretroviral therapy

Daniel B Chastain, Kayla R Stover, Daniel M Riche, Daniel B Chastain, Kayla R Stover, Daniel M Riche

Abstract

Introduction: As a result of improved safe and effective therapeutic options for human immunodeficiency virus (HIV), life expectancy of those living with HIV is increasing leading to new challenges (e.g., management of chronic diseases). Some chronic diseases (e.g., cardiovascular disease [CVD]), are up to two times more prevalent in patients with HIV. Statins are a mainstay of therapy for prevention of CVD; but, clinicians should be aware that not all statins are appropriate for use in the HIV population, especially those receiving antiretroviral therapy (ART). The purpose of this article is to review the pharmacokinetic and clinical data for statin therapy in HIV-infected patients receiving ART.

Methods: A systematic literature search using PubMed and MEDLINE databases was performed using each statin drug name combined with HIV, pharmacokinetics, AIDS, and/or human immunodeficiency virus. English language trials published from 1946 to November 2016 were considered, and results were limited to clinical efficacy trials.

Results: In general, atorvastatin and pravastatin are safe and effective for patients treated with protease-inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor-based ART. Rosuvastatin is generally considered safe if started at a low dose, but should be avoided if possible in patients receiving PI-based ART. Pitavastatin has limited supporting evidence, but appears safe for use based on its pharmacokinetic properties and low number of drug interactions. Fluvastatin, lovastatin, and simvastatin should be avoided in patients receiving ART due to drug interactions, adverse events, and/or limited clinical data.

Conclusion: Clinicians need to be familiar with the intricacies of statin selection for the prevention of CVD in patients with HIV on ART.

Keywords: Antiretroviral therapy; CVD; HIV; Lipids; Statins.

References

    1. UNAIDS. 90-90-90—an ambitious treatment target to help end the AIDS epidemic. Available at 90-90_en_0.pdf. Accessed September 24, 2016.
    1. Hall H.I., An Q., Tang T., Song R., Chen M., Green T., Kang J. Centers for Disease Control and Prevention (CDC). Prevalence of diagnosed and undiagnosed HIV infection-United States, 2008–2012. MMWR Morb Mortal Wkly Rep. 2015;64(24):657–662.
    1. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Ford N, Hill A. Can the UNAIDS 90–90-90 target be reached? Analysis of 12 national level HIV treatment cascades. Abstract MOAD0102, International AIDS Society (IAS), Vancouver, Canada, July 19–22, 2015.
    1. Sepkowitz K.A. AIDS–the first 20 years. N Engl J Med. 2001;344(23):1764–1772.
    1. Marcus JL, Chao C, Leyden W, Xu L, Quesenberry CP, Klein DB, Towner WJ, Horberg MA, Silverberg MJ. Narrowing the Gap in Life Expectancy for HIV+ Compared With HIV- Individuals. Abstract 54, Conference on Retroviruses and Opportunistic Infections (CROI), Boston, Massachusetts, February 22–25, 2016.
    1. Smit M., Brinkman K., Geerlings S., Smit C., Thyagarajan K., Sighem A.V. ATHENA observational cohort. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15(7):810–818.
    1. Trickey A., May M.T., Vehreschild J., Obel N., Gill M.J., Crane H. Antiretroviral Therapy Cohort Collaboration (ART-CC). Cause-specific mortality in hiv-positive patients who survived ten years after starting antiretroviral therapy. PLoS ONE. 2016;11(8):e0160460.
    1. Chastain D.B., Henderson H., Stover K.R. Epidemiology and management of antiretroviral-associated cardiovascular disease. Open AIDS J. 2015;9:23–37.
    1. Triant V.A., Lee H., Hadigan C., Grinspoon S.K. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92(7):2506–2512.
    1. Freiberg M.S., Chang C.C., Kuller L.H., Skanderson M., Lowy E., Kraemer K.L. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med. 2013;173(8):614–622.
    1. Currier J.S., Taylor A., Boyd F., Dezii C.M., Kawabata H., Burtcel B. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33(4):506–512.
    1. Lorenz M.W., Stephan C., Harmjanz A., Staszewski S., Buehler A., Bickel M. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis. 2008;196(2):720–726.
    1. Kuller L.H., Tracy R., Belloso W., De Wit S., Drummond F., Lane H.C. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.
    1. Eckard A.R., Meissner E.G., Singh I., McComsey G.A. Cardiovascular disease, statins, and HIV. J Infect Dis. 2016;214(Suppl 2):S83–S92.
    1. DAD Study Group, Friis-Møller N., Reiss P., Sabin C.A., Weber R., Monforte A.D. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356(17):1723–1735.
    1. Mary-Krause M., Cotte L., Simon A., Partisani M., Costagliola D., Clinical Epidemiology Group from the French Hospital Database Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17(17):2479–2486.
    1. Visnegarwala F., Maldonado M., Sajja P., Minihan J.L., Rodriguez-Barradas M.C., Ong O. Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice. J Infect Dis. 2004;49:283–290.
    1. Hulgan T., Sterling T.R., Daugherty J., Arbogast P.G., Raffanti S., Ray W. Prescribing of contraindicated protease inhibitor and statin combinations among HIV-infected persons. J Acquir Immune Defic Syndr. 2005;38:277–282.
    1. Ray G.M. Antiretroviral and statin drug-drug interactions. Cardiol Rev. 2009;17:44–47.
    1. Singh S., Willig J.H., Mugavero M.J., Crane P.K., Harrington R.D., Knopp R.H. Comparative effectiveness and toxicity of statins among HIV-infected patients. Clin Infect Dis. 2011;52:387–395.
    1. Stolbach A., Paziana K., Heverling H., Pham P. A review of the toxicity of hiv medications ii: interactions with drugs and complementary and alternative medicine products. J Med Toxicol. 2015;11(3):326–341.
    1. Sirtori C.R. The pharmacology of statins. Pharmacol Res. 2014;88:3–11.
    1. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63(25Pt B):2889–934.
    1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 3rd Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–3421.
    1. Zanni M.V., Fitch K.V., Feldpausch M., Han A., Lee H., Lu M.T. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014;28(14):2061–2070.
    1. Law M.G., Friis-Møller N., El-Sadr W.M., Weber R., Reiss P., D'Arminio Monforte A. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A: D Study. HIV Med. 2006;7(4):218–230.
    1. Grunfeld C., Delaney J.A., Wanke C., Currier J.S., Scherzer R., Biggs M.L. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS. 2009;23(14):1841–1849.
    1. Periard D., Cavassini M., Taffé P., Chevalley M., Senn L., Chapuis-Taillard . Cohort Study. High prevalence of peripheral arterial disease in HIV-infected persons. Clin Infect Dis. 2008;46(5):761–767.
    1. Mercié P., Thiébaut R., Aurillac-Lavignolle V., Pellegrin J.L., Yvorra-Vives M.C., Cipriano C. Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA). Carotid intima-media thickness is slightly increased over time in HIV-1-infected patients. HIV Med. 2005;6(6):380–387.
    1. Rasmussen L.D., Kronborg G., Larsen C.S., Pedersen C., Gerstoft J., Obel N. Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS ONE. 2013;8(3):e52828.
    1. Jacobson T.A., Ito M.K., Maki K.C., Orringer C.E., Bays H.E., Jones P.H. National lipid association recommendations for patient-centered management of dyslipidemia: part 1–full report. J Clin Lipidol. 2015;9(2):129–169.
    1. Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV, Underberg JA; NLA Expert Panel. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. J Clin Lipidol 2015;9(6 Suppl):S1–122.e1.
    1. Chong P.H., Seeger J.D. Atorvastatin calcium: an addition to HMG-CoA reductase inhibitors. Pharmacotherapy. 1997;17(6):1157–1177.
    1. Myerson M., Malvestutto C., Aberg J.A. Management of lipid disorders in patients living with HIV. J Clin Pharmacol. 2015;55(9):957–974.
    1. Fichtenbaum C.J., Gerber J.G., Rosenkranz S.L., Segal Y., Aberg J.A., Blaschke T. NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16(4):569–577.
    1. Carr RA, Andre AK, Bertz RJ, Lam W, Chang M, Chen P, Williams L, Bernstein B, Sun E. Concomitant administration of ABT-378/ritonavir (ABT-378/r) results in a clinically important pharmacokinetics (PK) interaction with atorvastatin (ATO) but not pravastatin (PRA). Abstract 1644, 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Toronto, Canada, September 17–20, 2000.
    1. Sherman E.M., Worley M.V., Unger N.R., Gauthier T.P., Schafer J.J. Cobicistat: review of a pharmacokinetic enhancer for HIV infection. Clin Ther. 2015;37(9):1876–1893.
    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at . (Accessed on December 3, 2016).
    1. Murillas J., Martín T., Ramos A., Portero J.L. Atorvastatin for protease inhibitor-related hyperlipidaemia. AIDS. 1999;13(11):1424–1425.
    1. Palacios R., Santos J., González M., Ruiz J., Valdivielso P., Márquez M. Efficacy and safety of atorvastatin in the treatment of hypercholesterolemia associated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;30(5):536–537.
    1. Calza L., Manfredi R., Colangeli V., Pocaterra D., Pavoni M., Chiodo F. Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors. Curr HIV Res. 2008;6(6):572–578.
    1. Lo J., Lu M.T., Ihenachor E.J., Wei J., Looby S.E., Fitch K.V. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV. 2015;2(2):e52–e63.
    1. Pravastatin sodium (Pravachol®) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2016.
    1. Ieiri I., Tsunemitsu S., Maeda K. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs. J Clin Pharmacol. 2013;53(6):654–661.
    1. Moyle G.J., Buss N.E., Gazzard B.G. Pravastatin does not alter protease inhibitor exposure or virologic efficacy during a 24-week period of therapy. J Acquir Immune Defic Syndr. 2002;30(4):460–462.
    1. Bonnet F., Aurillac-Lavignolle V., Breilh D. Pravastatin in HIV-infected patients treated with protease inhibitors: a placebo-controlled randomized study. HIV Clin Trials. 2007;8(1):53–60.
    1. Suttels V., Florence E., Leys J., Vekemans M., Van den Ende J., Vlieghe E. A 68-year old male presenting with rhabdomyolysis-associated acute kidney injury following concomitant use of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and pravastatin/fenofibrate: a case report. J Med Case Rep. 2015;9:190.
    1. Gerber J.G., Rosenkranz S.L., Fichtenbaum C.J. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J Acquir Immune Defic Syndr. 2005;39(3):307–312.
    1. van Luin M., Colbers A., van Ewijk-Beneken-Kolmer E.W. Drug-drug interactions between raltegravir and pravastatin in healthy volunteers. J Acquir Immune Defic Syndr. 2010;55:82–86.
    1. Baldini F., Di Giambenedetto S., Cingolani A., Murri R., Ammassari A., De Luca A. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. AIDS. 2000;14(11):1660–1662.
    1. Moyle G.J., Lloyd M., Reynolds B., Baldwin C., Mandalia S., Gazzard B.G. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS. 2001;15(12):1503–1508.
    1. Calza L., Manfredi R., Chiodo F. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS. 2003;17(6):851–859.
    1. Stein J.H., Merwood M.A., Bellehumeur J.L., Aeschlimann S.E., Korcarz C.E., Underbakke G.L. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J. 2004;147(4):E18.
    1. Hürlimann D., Chenevard R., Ruschitzka F., Flepp M., Enseleit F., Béchir M. Effects of statins on endothelial function and lipid profile in HIV infected persons receiving protease inhibitor-containing anti-retroviral combination therapy: a randomised double blind crossover trial. Heart. 2006;92(1):110–112.
    1. Calza L., Manfredi R., Colangeli V., Tampellini L., Sebastiani T., Pocaterra D. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS. 2005;19(10):1051–1058.
    1. Aberg J.A., Zackin R.A., Brobst S.W. A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087. AIDS Res Hum Retroviruses. 2005;21(9):757–767.
    1. Mallon P.W., Miller J., Kovacic J.C., Kent-Hughes J., Norris R., Samaras K. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men–a randomized, placebo-controlled study. AIDS. 2006;20(7):1003–1010.
    1. Baker J.V., Huppler Hullsiek K., Prosser R., Duprez D., Grimm R., Tracy R.P. Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial. PLoS ONE. 2012;7(10):e46894.
    1. Kietsiriroje N., Leelawattana R. Effects of pravastatin, phytosterols, and combination therapy on lipid profile in HIV-infected patients: an open-labelled, randomized cross-over study. BMC Res Notes. 2015;8:294.
    1. Grandi A.M., Nicolini E., Rizzi L., Caputo S., Annoni F., Cremona A.M. Dyslipidemia in HIV-positive patients: a randomized, controlled, prospective study on ezetimibe+fenofibrate versus pravastatin monotherapy. J Int AIDS Soc. 2014;17:19004.
    1. Rosuvastatin calcium (Crestor®) [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2016.
    1. Chauvin B., Drouot S., Barrail-Tran A., Taburet A.M. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52:815–831.
    1. Gervasoni C., Riva A., Rizzardini G., Clementi E., Galli M., Cattaneo D. Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients. Antivir Ther. 2015;20(4):449–451.
    1. Pham P.A., la Porte C.J.L., Lee L.S., van Heeswijk R., Sabo J.P., Elgadi M.M. Differential effects of tipranavir plus ritonavir on atorvastatin or rosuvastatin pharmacokinetics in healthy volunteers. Antimicrob Agents Chemother. 2009;53(10):4385–4392.
    1. Funderburg N.T., Jiang Y., Debanne S.M., Labbato D., Juchnowski S. Rosuvastatin reduces vascular inflammation and T cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;68(4):396–404.
    1. Aslangul E., Assoumou L., Bittar R., Valantin M.A., Kalmykova O., Peytavin G. Rosuvastatin versus pravastatin in dyslipidemic HIV-1 infected patients receiving protease inhibitors: a randomized trial. AIDS. 2010;24(1):77–83.
    1. Calza L., Colangeli V., Manfredi R., Legnani G., Tampellini L., Procaterra D. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS. 2005;19:1103–1108.
    1. Calza L., Manfredi R., Colangeli V., Trapani F.F., Salvadori C., Magistrelli E. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk. AID Res Hum Retroviruses. 2013;29(3):547–556.
    1. Longenecker C.T., Hileman C.O., Funderburg N.T., McComsey G.A. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis. 2014;59(8):1148–1156.
    1. Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, Robinson J, Lederman MM, McComsey GA. Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin Infect Dis. 2014;58(4):588-95.
    1. Erlandson K.M., Jiang Y., Debanne S., McComsey G.A. Effects of randomized rosuvastatin compared to placebo on bone and body composition among HIV-infected adults. AIDS. 2015;29(2):175–182.
    1. Eckard A.R., Jiang Y., Debanne S.M., Funderburg N.T., McComsey G.A. Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy. J Infect Dis. 2014;209:1156–1164.
    1. Dirajlal-Fargo Do S., Kinley B., Jiang Y., Longenecker C.T., Hileman C.O., DeBanne S. Statin therapy decreases NT-proBNP in HIV: randomized placebo-controlled trial. AIDS. 2015;29(3):313–321.
    1. Guidelines. Version 8.1. European AIDS Clinical Society. Updated October 2016. Available at . (Accessed on January 23, 2017).
    1. Garnett W.R. A review of current clinical findings with fluvastatin. Am J Cardiol. 1996;78(6A):20–25.
    1. Hsu A., Granneman G.R., Bertz R.J. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998;35(4):275–291.
    1. Long M.C., King J.R., Acosta E.P. Pharmacologic aspects of new antiretroviral drugs. Curr HIV/AIDS Rep. 2009;6(1):43–50.
    1. Doser N., Kübli S., Telenti A., Marzolini C., Chave J.P., Feihl F. Efficacy and safety of fluvastatin in hyperlipidemic protease inhibitor-treated HIV-infected patients. AIDS. 2002;16(14):1982–1983.
    1. Benesic A., Zilly M., Kluge F., Weissbrich B., Winzer R., Klinker H. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir. Infection. 2004;32(4):229–233.
    1. Pitavastatin (Livalo®) [package insert]. Montgomery, AL: Kowa Pharmaceuticals America, Inc; 2013.
    1. Gilbert J.M., Fitch K.V., Grinspoon S.K. HIV-related cardiovascular disease, statins, and the REPRIEVE trial. Topics Antiviral Med. 2015;23(4):146–149.
    1. Malvestutto C.D., Ma Q., Morse G.D., Underberg J.A., Aberg J.A. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr. 2014;67(4):390–396.
    1. Yu C.Y., Campbell S.E., Sponseller C.A., Small D.S., Medlock M.M., Morgan R.E. Steady-state pharmacokinetics of darunavir/ritonavir and pitavastatin when co-administered to healthy adult volunteers. Clin Drug Invest. 2014;34:475–482.
    1. Sponseller CA, Kryzhanovski VA, Morgan RE, Campbell SE, Thompson MA, Aberg JA. After 52 weeks, pitavastatin is superior to pravastatin for LDL-C lowering in patients with HIV. CROI 2014 Conference on Retroviruses and Opportunistic Infections. Abstract 751LB. Boston, MA, USA. March 2014.
    1. Wongprikorn A., Sukasem C., Puangpetch A., Numthavej P., Thakkinstian A., Kiertiburanakul S. Effects of pitavastatin on lipid profiles in HIV-infected patients with dyslipidemia and receiving atazanavir/ritonavir: a randomized, double-blind, crossover study. PLoS ONE. 2016;11(6):e0157531.
    1. Dubé M.P., Stein J.H., Aberg J.A., Fichtenbaum C.J., Gerber J.G., Tashima K.T. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37(5):613–627.
    1. Hsyu P.H., Schultz-Smith M.D., Lillibridge J.H., Lewis R.H., Kerr B.M. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45(12):3445–3450.
    1. Hare C.B., Vu M.P., Grunfeld C., Lampiris H.W. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis. 2002;35(10):e111–e112.
    1. Cheng C.H., Miller C., Lowe C., Pearson V.E. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm. 2002;59(8):728–730.
    1. Fichtenbaum C.J., Gerber J.G. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 2002;41(14):1195–1211.
    1. Schmidt G.A., Hoehns J.D., Purcell J.L., Friedman R.L., Elhawi Y. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin, amiodarone, and atazanavir. J Am Board Fam Med. 2007;20(4):411–416.
    1. Rahman A.P., Eaton S.A., Nguyen S.T., Bain A.M., Payne K.D., Bedimo R. Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy. Pharmacotherapy. 2008;28(7):913–919.
    1. Sekhar R.V. Treatment of dyslipidemia in HIV. Curr Atheroscler Rep. 2015;17(4):493.
    1. Gerber J.G., Kitch D.W., Fichtenbaum C.J. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186. J Acquir Immune Defic Syndr. 2008;47:459–466.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren